TRIAL DETAIL

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Drug:
Trial Name:
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
NCT#:
Conditions:
Sarcoma
Status:
Active, not recruiting
Phase:
2
Start Date 08/01/2016
Age of Trial (yrs) 8.3
Treatment Phase:
Gleevec-resistant
Drug Category:
PD-L1 + CTLA-4 inhibitor
Strategy:
Immune checkpoint inhibitor
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
2015-1071 NCI-2016-01178 ( Other Identifier: NCI CTRP )
Sponsor:
M.D. Anderson Cancer Center
Patient Contact:
Neeta Somaiah, MBBS 713-792-3626
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Official Title: A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Arms: Official Title: A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Exclusion Criteria:

Prior therapy with anti-PD1, anti-PD-L1 or anti-CTLA-4 antibody

Trial Links

Trial Results

Drug Information
Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299-308.
 

Trial Sites

Name
Address
City
State
Zip
Country
1505 Holcombe Blvd.
Houston
TX
77030
USA